Revelation Biosciences, Inc. announced positive safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients.
Gemini, the experimental drug, showed significant reduction in inflammatory activity at the cellular level.
Results indicate potential breakthrough in treating acute and chronic inflammatory diseases.
Safety and Activity Data
Gemini demonstrated safety and activity in Phase 1b PRIME clinical study.
Cellular Level Impact
Gemini normalized inflammatory response at cellular level in stage 3 and 4 CKD patients.
Treatment Potential
Gemini could revolutionize treatment of acute and chronic inflammatory diseases.
- Gemini significantly reduced inflammation and restored normal cellular response, indicating a breakthrough in inflammation treatment.
- Results suggest Gemini's ability to durably rebalance the inflammatory process at the cellular level.
The results from the PRIME study mark a significant advancement in inflammation treatment with Gemini showing promising results in CKD patients. This breakthrough could have a profound impact on future treatments for inflammatory diseases.